Futura Medical PLC, a consumer healthcare company specializing in the development and global commercialization of innovative sexual health products, has provided an update on its block listings. The company's block listings include options over Ordinary Shares of 0.2 pence each. The schemes covered in the update are the Unapproved Share Option Scheme, Unapproved Share Incentive Scheme, EMI Share Option Scheme, and LTIP Scheme.

As of 31 May 2024, the balance of unallotted securities under the schemes from the previous return was 20,782,665. There were no increases in the block schemes since the last return, and no securities were issued or allotted under the schemes during the period, resulting in a balance of 20,782,665 securities not yet issued or allotted at the end of the period.

Futura Medical's lead product, Eroxon, is a clinically proven topical gel developed for the treatment of Erectile Dysfunction (ED). It is the only topical gel treatment for ED available over the counter and is designed to help men achieve an erection in ten minutes, addressing significant unmet needs in the ED market. ED affects 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses occurring in men under 40.

For further information, the company's contacts are provided, including the Chief Executive Officer and the Finance Director and COO. Futura Medical's core strength lies in its research, development, and commercialization of topically delivered gel formulations in sexual health products.

The company's Nominated Adviser and Broker are Liberum, and Stifel Nicolaus Europe Limited serves as the Joint Broker. Alma Strategic Communications handles the company's media relations.

This update provides insight into Futura Medical's ongoing efforts in the development and commercialization of innovative sexual health products, particularly its lead product, Eroxon, aimed at addressing the significant unmet needs in the ED market.